anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to physical training and sport and is intended for the tactical preparation of sports men and women, for assessing the optical, cognitive and motor capabilities thereof. With the aim of increasing the effectiveness of preparing sports men and women, training is carried out with devices forming an expanded reality for the sports men and women. The training is presented to the sports men and women in the form of expanded 2D and 3D images of a surrounding space which is unpredictable for the sports man or woman, according to a program in a set of hardware and software, and the transparency, illumination, shape of the players and objects, the size thereof, the volume, the speed of movement and position in the volume of the specified training space are changed. The claimed method makes it possible to provide, at a qualitatively new level, tactical preparation of a sports man or women, to develop playing mentality, group actions and to individualize various training tasks according to purpose and complexity. The special-purpose, multi-variant simulation of playing situations with expanded reality, presented by said combination of 2D and 3D images, ensures a synergistic effect. The training is maximally variable, close to real competition conditions and has the effect of the presence of a rival and a trainer.
This is an unblinded, sequential study in which all participants will receive intravenous (IV) infusions of oxytocin in the same manner (except for safety reasons an adjustment at the highest level after review of the first 7 study participants as indicated in safety plan). In this study healthy people and with those with knee arthritis so severe that a joint replacement is needed are recruited for a one day study. Study participants will come to the Clinical Research Unit (CRU) and two IVs inserted; one in each forearm. Study participants will have an intravenous infusion of oxytocin at infusion rates that will result in a steady concentration of oxytocin in the blood for 15 minutes. The infusion rate will be increased every 15 minutes for a total of 4 targeted levels. Blood (5 millilitres (ml)) will be withdrawn through the IV not being used for infusion at the end of each of these infusion levels and the amount of oxytocin measured in the blood samples. This information will be analyzed by another group at Stanford University in the Pharmacokinetics/Pharmacodynamics (PK/PD) Core part of this application. The core group at Stanford University will use mathematics to test the accuracy of the infusion to target the blood concentration.

The main purpose of this study is to define the maximum effect oxytocin has on pain from a 5 minute heat probe applied to the skin and to get an estimate for the relationship between the amounts of pain relief at different amounts of oxytocin in the blood. The study team will use a commercially available device (Medoc TSA II) to heat a probe on the skin to 113 degrees Fahrenheit (45 degrees Celsius) for 5 minutes. Study participants will score any pain noted on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale. The study team will do this 5 times during the study, once before the infusion and once during each of the 4 levels of infusion. From this the study team will calculate how the amount of oxytocin in the blood affects pain.
The methods available for treating metastatic Ewing sarcoma (ES) are inadequate; thus, innovative therapeutic approaches need to be developed. However, the lack of clinically relevant ES models has hindered the discovery of drugs for this disease. In this study, we established and characterized a patient-derived xenograft (PDX) cell line model, which was constructed using tumor tissue from a patient with metastatic extraskeletal ES. The cells were found to recapitulate the morphological and histopathological features of the patient tumor and were designated as ES-ZSS-1. The cells harbor the characteristic EWSR1-FLI1 infusion and underwent successive passages in vitro. By performing gene expression profiling, we found that the mutation in STAG2 was the most frequent. An increase in Twist1 and epithelial-to-mesenchymal transition (EMT) was recorded. These genetic features might be relevant to metastasis and resistance to chemotherapy. To summarize, the novel patient-derived ES cell line we developed closely mimics the phenotype and genotype of patient tumors, making it a reliable tool for research on metastatic ES.
Athletes and patients aged 15 - 60 will receive standard sports concussion evaluations at the Duke Sports Science Institute (SSI) and will learn about the study by the primary clinicians evaluating sports concussion at the SSI. Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team in a stamped envelope. We expect to enroll 20 subjects.

If a subject has significant worsening of their symptoms and wishes to discontinue the study, they are requested to contact the study PI, Joel Morgenlander, MD. At that time, Dr. Morgenlander will document the specific reasons for discontinuation of the protocol. All follow-up care for their concussion will be through the provider they are already seeing for concussion. There is no significant risk to the athlete for participation except possible transient increase in their concussion symptoms. Benefits include possible hastening of recovery from their concussive symptoms and receiving training in mindfulness and yoga from a certified yoga instructor.
Transmembrane water permeability changes occur after initialization of necrosis and are a mechanism for early detection of cell death. Filter-exchange spectroscopy (FEXSY) is sensitive to transmembrane water permeability and enables its quantification by magnetic resonance via the apparent exchange rate (AXR). In this study, we investigate AXR changes during necrotic cell death. FEXSY measurements of yeast cells in different necrotic stages were performed and compared with established fluorescence cell death markers and pulsed gradient spin echo measurements. Furthermore, the influence of T2 relaxation on AXR was examined in a two-compartment system. The AXR of yeast cells increased slightly after incubation with 20% isopropanol, whereas it peaked sharply after incubation with 25% isopropanol. At this point, almost all the yeast cells were vital but showed compromised membranes. After incubation with 30% isopropanol, AXR measurements showed high variability, at a point corresponding to a majority of the yeast cells being in late-stage necrosis with disrupted cell membranes. Simulations revealed that, for FEXSY measurements in a two-compartment system, a long filter echo time (TEf), compared with the T2 of the slow-diffusing compartment, filters out a fraction of the slow-diffusing compartment signal and leads to overestimation of apparent diffusion coefficient (ADC) and underestimation of AXR. Our results demonstrate that AXR is sensitive to gradual permeabilization of the cell membrane of living cells in different permeabilization stages without exogenous contrast agents. AXR measurements were sensitive to permeability changes induced by relatively low concentrations of isopropanol, at levels for which no measurable effect was detectable by ADC measurements. TEf may act as a signal filter that affects the estimated AXR value of a system consisting of a variety of local diffusivities and a range of T2 that includes T2 values shorter or comparable with the TEf.
KALETRA oral solution dosed up to 300/75 mg/m2 has been studied in 100 pediatric patients 6 months to 12 years of age. The adverse reaction profile seen during Study 940 was similar to that for adult patients. 

Dysgeusia (22%), vomiting (21%), and diarrhea (12%) were the most common adverse reactions of any severity reported in pediatric patients treated with combination therapy for up to 48 weeks in Study 940. A total of 8 patients experienced adverse reactions of moderate to severe intensity. The adverse reactions meeting these criteria and reported for the 8 subjects include: hypersensitivity (characterized by fever, rash and jaundice), pyrexia, viral infection, constipation, hepatomegaly, pancreatitis, vomiting, alanine aminotransferase increased, dry skin, rash, and dysgeusia. Rash was the only event of those listed that occurred in 2 or more subjects (N = 3).

KALETRA oral solution dosed at 300/75 mg/m2 has been studied in 31 pediatric patients 14 days to 6 months of age. The adverse reaction profile in Study 1030 was similar to that observed in older children and adults. No adverse reaction was reported in greater than 10% of subjects. Adverse drug reactions of moderate to severe intensity occurring in 2 or more subjects included decreased neutrophil count (N=3), anemia (N=2), high potassium (N=2), and low sodium (N=2). 

KALETRA oral solution and soft gelatin capsules dosed at higher than recommended doses including 400/100 mg/m2 (without concomitant NNRTI) and 480/120 mg/m2 (with concomitant NNRTI) have been studied in 26 pediatric patients 7 to 18 years of age in Study 1038. Patients also had saquinavir mesylate added to their regimen at Week 4. Rash (12%), blood cholesterol abnormal (12%) and blood triglycerides abnormal (12%) were the only adverse reactions reported in greater than 10% of subjects. Adverse drug reactions of moderate to severe intensity occurring in 2 or more subjects included rash (N=3), blood triglycerides abnormal (N=3), and electrocardiogram QT prolonged (N=2). Both subjects with QT prolongation had additional predisposing conditions such as electrolyte abnormalities, concomitant medications, or pre-existing cardiac abnormalities.

Laboratory Abnormalities

The percentages of pediatric patients treated with combination therapy including KALETRA with Grade 3-4 laboratory abnormalities are presented in Table 8.
The visceral adiposity index (VAI) and handgrip strength (HGS) are identified as important objectives for the prevention of illness. Nevertheless, there is limited understanding regarding the impact of the VAI and HGS on cardiometabolic multimorbidity (CMM). We aimed to ascertain the impact of the VAI and HGS on CMM among middle-aged and older people. Data spanning from 2011 to 2020 were derived from the China Health and Retirement Longitudinal Study (CHARLS). In total, 7909 individuals aged 45 years and older were included. Cox proportional hazard regression was utilized to examine the correlation among the VAI, HGS, and CMM. Throughout the 10-year follow-up, we determined that both the VAI (HR = 1.330; 95%CI = 1.179-1.500) and HGS (HR = 0.745, 95%CI = 0.645-0.861) exhibited significant associations with CMM risk. Individuals exposed to both a high VAI and low HGS were found to have higher hazards of CMM (HR = 1.377, 95%CI = 1.120-1.694) in contrast to participants exposed to one or none of these conditions. The older (HR = 1.414; 95%CI = 1.053-1.899) and male (HR = 1.586; 95%CI = 1.114-2.256) groups are more likely to experience CMM risk. Our findings suggest that both the VAI and HGS have significant effects on CMM risk. Appropriate interventions focused on vulnerable groups are recommended to prevent the incidence of CMM.
The non-coding RNAs comprise a large part of human genome lack of capacity in encoding functional proteins. Among various members of non-coding RNAs, the circular RNAs (circRNAs) have been of importance in the pathogenesis of human diseases, especially cancer. The circRNAs have a unique closed loop structure and due to their stability, they are potential diagnostic and prognostic factors in cancer. The increasing evidences have highlighted the role of circRNAs in the modulation of proliferation and metastasis of cancer cells. On the other hand, metastasis has been responsible for up to 90% of cancer-related deaths in patients, requiring more investigation regarding the underlying mechanisms modulating this mechanism. EMT enhances metastasis and invasion of tumor cells, and can trigger resistance to therapy. The cells demonstrate dynamic changes during EMT including transformation from epithelial phenotype into mesenchymal phenotype and increase in N-cadherin and vimentin levels. The process of EMT is reversible and its reprogramming can disrupt the progression of tumor cells. The aim of current review is to understanding the interaction of circRNAs and EMT in human cancers and such interaction is beyond the regulation of cancer metastasis and can affect the response of tumor cells to chemotherapy and radiotherapy. The onco-suppressor circRNAs inhibit EMT, while the tumor-promoting circRNAs mediate EMT for acceleration of carcinogenesis. Moreover, the EMT-inducing transcription factors can be controlled by circRNAs in different human tumors.
Left atrial (LA) epicardial adipose tissue (EAT) and wall fibrosis are both proven to contribute to the pathogenesis and progression of atrial fibrillation (AF). The theory of LA wall fibrosis induction by local EAT infiltration, paracrine secretions, and activation of the inflammatory process is strongly advocated, but the imaging evidence for anatomical proximity of the two tissue types and its association to AF stage is lacking. Accordingly, the aim of the study was to analyse the spatial overlap between LA EAT and adjacent wall fibrosis using 3D Dixon water-fat separated late gadolinium enhancement (LGE-Dixon) MRI and correlate the findings with the clinical AF stage. Forty-two AF patients (18 paroxysmal, 10 persistent, and 14 permanent) and nine non-AF patients were scanned. The permanent AF patients had greater LA volume and EAT than the paroxysmal group. The LA fibrosis area showed the same trend. The LA EAT-fibrosis overlap area was small and there was no significant difference between the three AF stages. There was no significant relationship between LA EAT- fibrosis overlap area and AF type. The findings shed light on the complex interplay between LA fibrosis and EAT during the progression from paroxysmal to permanent AF.
Systems and methods include a medical device that scans for wireless broadcasts based upon received input or satisfying a scanning criterion. The medical device, based upon the scan, identifies data wirelessly broadcast from a control device. The medical device outputs information to the interface identifying the control device. The medical device receives input from the interface selecting the control device. The medical device receives a command from the control device. The medical device physically interacts with a user based upon the command received from the control device. The medical device sends wireless confirmation of pairing to the control device. The medical device subsequently sends wireless confirmation of unpairing to the control device. The medical device performs a scan for wireless broadcasts in response to the unpairing, based upon received input or satisfying the scanning criterion.
This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m\^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m\^2) and cyclophosphamide (600 mg/m\^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
Nanoparticle-sized magnetic absorption enhancers (MAEs) that exhibit a controlled response to a magnetic field, including a controlled mechanical response and inductive thermal response. The MAEs have a magnetic material that exhibits the inductive thermal response to the magnetic field and is embedded in a coating, such that the MAE conforms to a particular shape, e.g., a hemisphere, a dome or a shell, that is chosen to produce the desired controlled mechanical response of the entire MAE to the magnetic field. A targeting moiety for specifically binding the MAE to a pathogen target is also provided. The MAEs are preferably bound by a flexible linker to promote the desired mechanical response, which includes interactions between MAEs that are not bound to their pathogen target for the purpose of forming spheres, spherical shells, or generally spherical dimers. Such forms contain the thermal energy produced by the thermal inductive response of the magnetic material and thus reduce collateral healthy tissue damage during hyperthermic treatment. The inventing extends to appropriate apparatus and methods for diagnostics and hyperthermic treatments employing the MAEs.
BACKGROUND: Inflammation is a significant factor in adverse health outcomes, but the combined effects of diets with varying oxidation levels and exposure to volatile organic compounds (VOCs) on inflammation are not well understood. This study aimed to elucidate the effects of the recognized Dietary Oxidative Balance Score (DOBS) and five VOCs on the systemic immune-inflammation index (SII) and C-reactive protein (CRP).
METHODS: This cross-sectional study included data from participants in three cycles (2003-2004, 2005-2006, 2009-2010) of the National Health and Nutrition Examination Survey (NHANES). We used Spearman correlation, logistic regression, and trend tests to explore the associations between DOBS, VOCs, SII, and CRP. Additionally, we conducted restricted cubic spline (RCS) analysis to assess dose-response relationships between exposure and effect. G-computation and stratified analyses were performed to further elucidate these associations.
RESULTS: We included 7033 eligible participants, with 48.8 % males and 51.2 % females. Spearman correlation revealed that DOBS was negatively correlated with SII and CRP, while the five VOCs were positively correlated with SII and CRP. Although fully adjusted logistic regression models did not yield statistically significant results, trend tests indicated a gradual decrease in SII and CRP with increasing DOBS, a finding validated by RCS analysis. G-computation results demonstrated that the combined effect of DOBS and VOCs on inflammation was positive, with DOBS exerting a negative effect and benzene, ethylbenzene, and 1,4-dichlorobenzene exerting positive effects. Stratified analysis showed that maintaining physical activity significantly influenced the effects of DOBS and VOCs on inflammation.
CONCLUSION: This study suggests that adjusting dietary structure and reducing daily exposure to VOCs can effectively reduce inflammation in the body.
The present invention relates to an oil-based preparation containing a triazine effective against parasitic protozoa and an anthelmintic cyclodepsipeptide, which is suitable in particular for oral application of the combination of active agents in animals. A methodology is provided for making UV-curable, wear resistant and antistatic coating filled with carbon nanotubes (CNTs). The composition consists of a mixture of CNTs, an acrylate-based monomer, a urethane-acrylate oligomer and a photoinitiator. The present invention provides a coating of which the wear resistance and antistatic properties are dramatically improved in comparison with the polymer substrate. This coating is suitable for protecting a variety of polymer substrates from scratch and electrostatic accumulation. The present invention relates to an oil-based preparation containing a triazine effective against parasitic protozoa and an anthelmintic cyclodepsipeptide, which is suitable in particular for oral application of the combination of active agents in animals.
A therapeutic dentifrice comprises a water-soluble inorganic fluoride as an essential fluoridising ingredient and microcrystalline aluminium hydroxide as an essential cleansing and polishing agent, any other cleaning and polishing agent present being of such a nature as not to react with the water soluble inorganic fluoride to form a water insoluble compound.  The dentrifice contains 0.1 to 2.0 per cent. fluoride, and microcrystalline aluminium hydroxide in the following percentages (a) powder 90 to 95, (b) paste 25 to 50 and (c) liquid 25 to 30. The microcrystalline aluminium hydroxide may be replaced in part by abrasives of larger particle size e.g. alumina and aluminium hydroxide.  Specified fluorides are sodium fluoride, potassium fluoride and stannous fluoride.  Optional ingredients are: (a) surface active agents e.g. soap, sodium lauryl sulphate, sodium lauryl sulphoacetate; amine and metal salts of alkyl sulphates, sulphonated fatty alcohols, aliphatic sulphonic acids and aliphatic substituted aromatic sulphonic acids; fatty acid amides of dialkylaminoalkyl amines and tertiary amino alkyl esters.  (b) flavouring agents e.g. vanillin, oils of cinnamon, clove, anise, fennel, lavender and eucalyptus, thymol, menthol, camphor and other terpenes (c) binders, excipients and lubricants e.g. glycerin, propylene glycol, gum karaya, Irish moss, gum acacia, tragacanth, agar agar, salts of carboxymethyl cellulose, sorbitol citrate; diethylene glycol diborate, mannitol oleate, pectin, sorbitol syrup, corn starch, glycerite of starch, glycerite of sodium stearate, sodium alginate, gelatin, glycols, fatty acid esters of glycerin and glycols, mineral oil, petroleum and alcohol.  (d) sweetening agents such as saccharin, sucrose, starch syrups, honey, dulcitol and lactose.  (e) preservatives such as methyl phydroxybenzoate and bis (3, 5, 6 trichloro-2-hydroxy phenyl) methane.  Liquid and paste dentifrices are preferably adjusted to pH 4.0 to 9.0, and in particular to H p5.0 to 7.5 where the fluoride is an alkali metal fluoride, and to pH 4.0 to 5.5 in the case of stannous fluoride. Specification 633,845 is referred to.
Cystic fibrosis (CF) is a genetic disease with an autosomal recessive, chronic and progressive character. About 10 to 25% of patients develop CF-related diabetes (DRFC), whose pathogenesis is associated with pancreatic fibrosis and destruction. Until now, there is no evidence to support the use of low glycemic index diet to improve glycemic response in pre-diabetic and CF patients. The objective of this study is to evaluate the glycemic improvement after nutritional orientation in patients with cystic fibrosis in the pre-diabetic phase. Methods: Randomized clinical trial in patients with CF aged over 10 years without hospitalization in the last 4 weeks. Anthropometric measurements, blood pressure, 24 hour recall and food frequency questionnaire will be evaluated. Oral glucose tolerance and glycated hemoglobin test will be dosed at baseline and during 12 weeks of follow-up. The intervention group will receive a nutritional guidance at the beginning of the research.